Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL
Michael Northend, William Wilson, Wendy Osborne, Christopher P. Fox, Andrew Davies, Dima El‐Sharkawi, Elizabeth H. Phillips, Hau Wui Sim, Shalal Sadullah, Nimish Shah, Ying Ying Peng, Iman Qureshi, Juanah Addada, Rocío Figueroa Mora, Neil Phillips, Andrea Kühnl, Elizabeth Davies, David Wrench, Pam McKay, Indrani Karpha, Anna Cowley, Richard Karim, Sarah Challenor, Vikram Singh, Cathy Burton, Rebecca Auer, Christopher Williams, Joel Cunningham, Angus Broom, Anita Arasaretnam, Claire Roddie, Tobias Menne, William Townsend
Abstract
For Pola-BR, the objective response rate (ORR) was 62.5% (complete response [CR] rate was 50%). Median progression-free survival (PFS) a at 9.2 months and overall survival (OS) at 12.4 months were both superior for Pola-BR. 9 A single-arm expansion cohort identified primary refractory